Zenas Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Zenas BioPharma announced positive Phase 3 results for obexelimab in IgG4-RD and promising Phase 2 RMS data, while reporting significant net losses and a going concern warning from its auditor.
NASDAQ
Zenas BioPharma details its 2024 financial performance, highlighting ongoing clinical trials and strategic collaborations in the immunology space.